Diana D Lobo

Center for Innovation — United States

Neuroscience · Life Sciences

5h-index191citations22works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Neurodegenerative Diseases(13), Mitochondrial Function and Pathology(7), RNA Interference and Gene Delivery(4), Parkinson's Disease Mechanisms and Treatments(3), RNA Research and Splicing(3)

Publications22 total

Mesenchymal Stromal Cell Therapeutic Potential to Restore Neurovascular Integrity in Machado-Joseph Disease
2026
Extracellular vesicles-associated AAVs for the treatment of Machado-Joseph disease
Molecular Therapy·2025· 1 citedOpen Access
rAAV-Delivered Bicistronic Artificial microRNAs for Allele-Specific Silencing Improve Motor and Molecular Outcomes in Spinocerebellar Ataxia Type 3
2025Open Access
AAV-mediated allele-specific silencing alleviates neuropathology in a novel non-human primate model of Spinocerebellar ataxia type 3
2025Open Access
Spinocerebellar ataxia type 3: from pathogenesis to promising therapeutics
Trends in Molecular Medicine·2025· 1 cited
Innate immunocompetent iNSpheroids: A hiPSC-derived 3D model to study the central nervous system captures an early CNS response to rAAV
2025Open Access
Circadian rhythms are disrupted in patients and preclinical models of Machado-Joseph disease
Brain·2025Open Access
A systematic screening assay identifies efficient small guide RNAs for CRISPR activation
Frontiers in Bioengineering and Biotechnology·2025· 1 citedOpen Access
Circadian Rhythms are Disrupted in Patients and Preclinical Models of Machado-Joseph Disease
2025· 1 citedOpen Access
JoVE Video Dataset
2024Open Access
Viral-based animal models in polyglutamine disorders
Brain·2024· 4 citedOpen Access
A systematic screening assay identifies efficient small guide RNAs for CRISPR activation
2023Open Access
Isolation of Biologically Active Extracellular Vesicles-Associated AAVs for Gene Delivery to the Brain by Size Exclusion Chromatography
2023· 1 citedOpen Access
Nuclear aging in polyglutamine-induced neurodegeneration
2023· 1 citedOpen Access
Isolation of Biologically Active Extracellular Vesicles-Associated AAVs for Gene Delivery to the Brain by Size Exclusion Chromatography
2023· 1 citedOpen Access
Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease/spinocerebellar ataxia type 3
Molecular Therapy·2023· 34 citedOpen Access
miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3
Nucleic Acid Therapeutics·2021· 22 citedOpen Access
ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease
Molecular Therapy·2021· 14 citedOpen Access
The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples
Acta Neuropathologica Communications·2020· 38 citedOpen Access
Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders
Brain·2019· 72 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Luís Pereira de Almeida(17), Rui Jorge Nobre(16), Carina Henriques(11), Sara Lopes(10), Miguel M. Lopes(10), Dina Pereira(8), Sónia Duarte(5), Kevin Leandro(5), Laetitia S. Gaspar(5), Ana Carolina da Silva(5), Inês M. Martins(4), Magda M. Santana(4), Ana C. Silva(3), João Castelhano(3), Miguel Castelo‐Branco(3), David Rufino‐Ramos(3), Rafael Baganha(3), Casey A. Maguire(3), Cláudia Cavadas(3), Ana Rita Fernandes(3)